3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
3
Genitourinary
3
Thoracic
2
Breast
2
Gastrointestinal
1
Conditions
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
120
Carboplatin
114
Pemetrexed
74
Cisplatin
71
Nivolumab
68
Paclitaxel
58
Docetaxel
56
Radiotherapy
41
Erlotinib Hydrochloride
41
Gemcitabine
35
Etoposide
34
atezolizumab
30
osimertinib
29
Cetuximab
27
Ipilimumab
25
Bevacizumab
25
Radiosurgery
22
durvalumab
21
Cyclophosphamide
20
Drug Therapy
18
130-nm albumin-bound paclitaxel
17
avelumab
14
Taxes
14
Gefitinib
14
Albumin-Bound Paclitaxel
14
Irinotecan
13
Injections
13
fludarabine
11
Radiation
11
cemiplimab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
AZD5305
×
Thoracic
×
Clear all
NCT05797168
2026-06-03
FONTANA
AstraZeneca
Phase 1/2
Recruiting
506 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled